abstract |
The cancer therapeutic agent according to the present invention is a cancer therapeutic agent comprising IL-18, an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, As an active ingredient. |